Ultragenyx Pharmaceutical to Monetize FDA Review Voucher for $203 Million
Ultragenyx Pharmaceutical, Inc. (RARE) reached a deal on Oct. 8, 2026, to hand over a pediatric priority review voucher to an undisclosed buyer for $203 million upfront. The regulatory ticket was originally granted on Sept. 17, 2026, when the FDA approved FAYUVI (UX111) to treat MPS IIIA.
By offloading the voucher, Ultragenyx Pharmaceutical aims to unlock quick capital to reinvest into key corporate goals. Meanwhile, shares of the drugmaker fell 2.48% to $14.92 during trading.
The deal requires standard closing approvals before it can officially finalize, including the clearance or expiration of the Hart-Scott-Rodino waiting period.
Key points
- Ultragenyx Pharmaceutical struck a deal to offload an FDA regulatory voucher for $203 million upfront.
- The agency awarded the voucher on Sept. 17, 2026, following the approval of FAYUVI (UX111) for MPS IIIA.
- Proceeds from the sale will provide cash to help Ultragenyx Pharmaceutical finance strategic goals.
- Completion of the transaction requires standard regulatory clearance under the HSR waiting period.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
How much cash will Ultragenyx receive from selling its FDA voucher?
Ultragenyx Pharmaceutical will receive $203 million in cash when the deal closes.
Why did Ultragenyx receive the Priority Review Voucher?
The FDA granted the voucher on Sept. 17, 2026, after approving FAYUVI (UX111) to treat MPS IIIA.
Who bought the Priority Review Voucher from Ultragenyx?
The buyer of the priority review voucher has not been identified.